智飞生物(300122) - 2017 Q1 - 季度业绩预告

Financial Performance - The company's net profit for Q1 2017 is expected to be between 44.39 million yuan and 62.16 million yuan, reflecting a potential decrease of 0-25% or an increase of 0-5% compared to the same period last year [2]. - The net profit, after excluding non-recurring gains and losses, is projected to decline by 0-25% or increase by 0-5% year-over-year [4]. - The performance forecast has not been audited by registered accountants, indicating preliminary estimates [4]. Market Conditions - The impact of the illegal vaccine incident from March 2016 is gradually diminishing, leading to a recovery in market conditions [3]. - The new policy for Category II vaccines is being implemented across various provinces, contributing to a more rational consumption and usage of vaccines by the public [3]. Management Strategy - The management is actively seizing opportunities to expand and is working towards achieving the annual operational goals [3]. - The financial data for Q1 2017 will be detailed in the upcoming quarterly report, urging investors to pay attention and manage investment risks [5].